Technology May Help Identify Pancreatic Cancer Surgery Patients

March 26, 1998

COLUMBUS, Ohio -- An experimental technique that helps identify colorectal-cancer patients who may best benefit from surgery may also work well on patients with pancreatic cancer, new research shows.

“This technology may help us decide who will benefit from more extensive surgery and who might be spared a major operation,” said Gregory LaValle, assistant professor of surgery and a researcher with Ohio State University's Comprehensive Cancer Center.

The technique helps surgeons determine how far a tumor has spread within the body. Patients whose cancer has spread beyond the site of the tumor often stand a very poor chance of being cured by the treatment. In fact, extensive surgery can do more harm than good in these patients by causing stress and trauma that reduces the patient’s quality of life.

Determining which patients will not benefit from extensive surgery is therefore important.

This study, which was led by LaValle, was published in a recent issue of the journal Surgery. The experimental technique uses an antibody labeled with radioactivity that binds to a protein produced by tumor cells. Patients are given the antibody intravenously a few weeks before surgery.

During surgery, the physician scans the abdomen with a hand-held probe searching for signs of radioactivity. In theory, the detection of radioactivity signals the presence of cancer cells. The technology is thought to be most useful for locating clusters of tumor cells that are too small to be visible in tissues and lymph nodes surrounding the tumor.

Locating these so-called “occult” tumor cells gives a more accurate idea of whether the tumor has spread beyond its site of origin, and, if so, how extensively it has spread. This information is essential for the surgeon to determine the stage of a patient’s cancer.

In general, stage-I cancer means the tumor has not spread beyond the organ in which it originated (i.e., it is localized). In many types of cancer, surgery can often cure these patients. In stage-II cancer, the tumor has invaded neighboring tissue; in stage III, it has spread (or metastasized) to nearby lymph nodes. By stage-IV, the tumor has spread to distant regions of the body.

Many cancers, including pancreatic cancer, are staged during surgery, when the oncologist can inspect the tumor and the surrounding organs and lymph nodes. Suspicious lymph nodes are removed and studied for signs of cancer cells. A hair-thin slice is taken from the node and examined using a microscope. If malignant cells are found, it indicates the tumor has spread.

This study compared staging pancreatic-cancer patients by the traditional inspection method to the results of staging them by inspection plus use of the antibody and hand-held probe.

The traditional method identified a total of 25 organ sites affected by cancer, while use of the probe identified a total of 29 organ sites. When lymph nodes were examined, the traditional method located six affected nodes, whereas use of the probe identified 44 sites.

The results suggested that the antibody and probe method may be better than the traditional method alone for detecting how far the tumor had spread.
Because the probe had identified so many more nodes than did the traditional method, the researchers did additional tests on nine nodes to verify that cancer was being detected in them. The tests further demonstrated the presence of cancer cells in six of the nine nodes; three did not. The researchers speculated that, among other things, these nodes may have contained only a small number of cancer cells and that these cells may have been missed by the analysis.

“This technique has already proven useful in patients with recurrent colorectal cancer,” said LaValle. “Our results suggest that with more research it might also help people with pancreatic cancer.”

Pancreatic cancer is the fifth leading cause of cancer deaths in the United States. It’s also a particularly deadly form of cancer, said LaValle. “The mortality rate from pancreatic cancer is at least 90 percent five years after diagnosis, whereas the five-year mortality rates from tumors like breast or colon cancer is less than 50 percent.”

The study was funded by the Neoprobe Corporation, which manufactures the antibody and hand-held probe.
Contact: Gregory LaValle, (614) 293-8700
Written by Darrell E. Ward, (614) 292-8456;

Ohio State University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to